Week 5 nr 546 - Study guides, Class notes & Summaries

NR 546 WEEK 7 ADHD Medication Table (Updated). Methylphenidate (D/L) (Concerta, Ritalin) -Dopamine, norepinephrine inhibitor and releaser (DNRIRe), stimulant, FDA approved for ADHD in children and adults (ages vary based on formulations), narcolepsy. Off-label for treatmentresistant depression. Enhancement DA and NE in certain areas of the brain (dorsolateral prefrontal cortex, medial prefrontal cortex). Primary target symptoms: concentration, attention span, motor hyperactivity,...

NR 546 Week 7 ADHD Medication Table Latest. Drug Name (include if IR, XR, ODT, LA) Indication (include approved ages) Neurotransmitter(s) Affected Target Symptoms Short-acting, intermediate-acting or long-acting. Duration of action, peak (if noted) Notable side effects /Patient education instructions Methylphenidate (D/L) (Concerta, Ritalin) Indication (include approved ages) Attention deficit hyperactivity disorder (ADHD) in children and adults (approved ages vary base...

Chamberlain NR 546 Week 5 Antidepressant and Mood Stabilizer Medication Table

NR 546 WEEK 1 Quiz TO Week 6 Quiz with Accurate answers NR546 WEEK 1 The amygdala is associated with anxiety and perception of odors. The hippocampus is involved in memory and anxiety. The amygdala is associated with anxiety and perception of odors. The prefrontal cortex is associated with executive function. The thalamus is associated with motor command processing The client’s cognitive status can result in an ethical concern if the client is unable to self-determine care or is a danger to se...

Week 5 NR 546 Questions With Complete Solutions

NR 546 Week 7 ADHD Medication Table Latest. Drug Name (include if IR, XR, ODT, LA) Indication (include approved ages) Neurotransmitter(s) Affected Target Symptoms Short-acting, intermediate-acting or long-acting. Duration of action, peak (if noted) Notable side effects /Patient education instructions Methylphenidate (D/L) (Concerta, Ritalin) Indication (include approved ages) Attention deficit hyperactivity disorder (ADHD) in children and adults (approved ages vary base...

Week 5 NR 546 Questions With Complete Solutions

Final Exam: NR546/ NR 546 (Latest Update 2024/ 2025) Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Review| Complete Guide with Questions and Verified Answers| 100% Correct- Chamberlain Q: SSRI MOA inhibit 5HT reuptake first line of treatment for depression Q: SSRI s/e Answer: 7 S's of SSRIs 1.Stomach l dysfunction onin syndrome difficulties dal thoughts s (weight) Q: serotonin s/e Answer: head, red, fed head = decreased anxiety, impul...

Midterm Exam: NR546/ NR 546 (NEW Update 2024/ 2025) Psychopharmacology for the Psychiatric-Mental Health Nurse Practitioner Review |Weeks 1-4 | Questions and Verified Answers| 100% Correct- Chamberlain QUESTION Haloperidol, ziprasidone, and olanzapine Answer: increased risk of CVA, cognitive decline, and death in older adults with dementia and dementia related psychosis QUESTION aripiprazole black box warning Answer: medication with increased risk of suicide in...

week 5 NR 546 Questions with correct answers